BiomEdit

About:

Microbiome Innovation for Animal Health

Website: https://www.biomedit.com/

Top Investors: Bill & Melinda Gates Foundation, Viking Global Investors, Anterra Capital, Nutreco

Description:

BiomEdit is an innovation company that discovers, designs, and develops novel probiotics, microbiome derived bioactives, and engineered microbial medicines to address unmet needs in animal health. Our ambition is to create solutions to some of the most important problems in animal agriculture and food security by leveraging the potential of the microbiome. BiomEdit’s technology is based on a unique platform that utilizes high-throughput sequencing and data analytics to rapidly discover and screen novel probiotic species and bioactive molecules. These can then be engineered to confer thermostability, enhanced production of beneficial metabolites, or expression of immune modulating proteins. These probiotics and microbially-derived compounds represent the next generation of products designed to promote animal health without the use of antibiotics.

Total Funding Amount:

$48.5M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Fishers, Indiana, United States

Founded Date:

2022-01-01

Founders:

Aaron Schacht

Number of Employees:

11-50

Last Funding Date:

2023-11-02

IPO Status:

Private

Industries:

© 2025 bioDAO.ai